Astragaloside IV exerts antiviral effects against coxsackievirus B3 by upregulating interferon-gamma.
Coxsackievirus B3 (CVB3) is a major pathogen for viral myocarditis and dilated cardiomyopathy in children and young adults. The aim of this study was to determine the antiviral effects of astragaloside IV against CVB3, and the underlying mechanism. First, we evaluated antiviral effects of astragaloside IV in vitro by measuring the virus titers of CVB3 in primarily cultured myocardial cells infected with CVB3, and in vivo by assessing the morbidity, mortality, heart-to-body weight ratio (HW/BW), and virus titers in BALB/c mice infected with CVB3. Then, we performed serum pharmacological experiments by testing the effect of sera from SD rats treated with astragaloside IV on proliferation of CVB3 in primarily cultured myocardial cells. Finally, we determined the effect of astragaloside IV on IFN-gamma mRNA expression in the hearts of infected BALB/c mice. We observed that astragaloside IV decreased virus titers of CVB3 in primarily cultured myocardial cells. Morbidity, mortality, HW/BW, and virus titers all decreased, and necrosis and mononuclear cell infiltration were alleviated in CVB3-infected mice treated with astragaloside IV, compared with those infected mice without the treatment. In addition, proliferation of CVB3 was inhibited by the sera of rats treated with astragaloside IV. Moreover, we observed that IFN-gamma mRNA expression was increased in mice treated with astragaloside IV. Therefore, we conclude that astragaloside IV exerts antiviral effects against CVB3 by upregulating expression of IFN-gamma mRNA.
Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.
Yuanyuan
Y
Zhang
Haiyan
H
Zhu
Chenggang
C
Huang
Xiaolan
X
Cui
Yingjie
Y
Gao
Yang
Y
Huang
Wenfeng
W
Gong
Ye
Y
Zhao
Shanshan
S
Guo
D000818:Animals; D000831:Animals, Newborn; D000998:Antiviral Agents / Q000737:chemistry / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D003384:Coxsackievirus Infections / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000821:virology; D029822:Enterovirus B, Human / Q000502:physiology*; D007274:Injections, Intraperitoneal; D007371:Interferon-gamma / Q000096:biosynthesis*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D015394:Molecular Structure; D009205:Myocarditis / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000821:virology; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D012333:RNA, Messenger / Q000378:metabolism; D012503:Saponins / Q000737:chemistry / Q000494:pharmacology*; D014315:Triterpenes / Q000737:chemistry / Q000494:pharmacology*; D015854:Up-Regulation; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D012333:RNA, Messenger; D012503:Saponins; D014315:Triterpenes; C052064:astragaloside A; D007371:Interferon-gamma